Drug Search Results
More Filters [+]

Lisuride

Alternative Names: lisuride, dopergin
Latest Update: 2023-09-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: D2 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Subcutaneous,Transdermal

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Chile | Colombia | Dominican Republic | Egypt | France | Germany | Ireland | Italy | Mexico | New Zealand | Pakistan | Peru | Portugal | Taiwan | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Axxonis Pharma AG
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lisuride

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Parkinson's Disease|Restless Legs Syndrome|Psychomotor Agitation

Phase 2: Parkinson's Disease|Hypertension, Pulmonary

Phase 1: Cocaine-Related Disorders

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Lis-Safe

P2

Terminated

Hypertension, Pulmonary

2014-08-19

CALIPSO

P3

Completed

Parkinson's Disease

2009-10-02

TULEP 1

P3

Active, not recruiting

Parkinson's Disease

2008-09-20

Tulir03/01

P3

Active, not recruiting

Restless Legs Syndrome

2007-09-08

Recent News Events